Leveraging AI-Driven Trial Design and Omnimodal Comprehensive Analysis to Prioritize Indications, Stratify Patients and De-Risk Clinical Development

WALTHAM, Mass.: BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced that it will showcase its latest advances at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo, the premier global gathering of molecular professionals driving innovation in diagnostics, drug development and patient care. The event is scheduled for November 11–15, 2025, at the Thomas M. Menino Convention and Exhibition Center in Boston, Massachusetts.

During the conference, BostonGene will host the session “AI-Data-Driven Trial Design: Advanced Digital Models and Multimodal Testing Tools” in collaboration with Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and the Miller School of Medicine. This joint session pairs BostonGene’s leadership in omnimodal AI with Sylvester’s clinical expertise to demonstrate real-world applications of AI in trial design.

This session will explore how BostonGene’s omnimodal foundation model combines genomic, transcriptomic and immune data to identify patient subgroups, guide biomarker discovery and inform treatment strategies. By applying AI-driven analysis and digital-twin approaches, BostonGene brings greater precision, adaptability and efficiency to trial design. Complex multiomic solutions are distilled into clinically deployable patient selection criteria measurable with standard-of-care diagnostic approaches. Attendees will learn how omnimodal platforms enhance predictions resulting in targeted trials that accelerate drug development-shaping the next generation of data-driven clinical research and advancing the promise of personalized medicine.

Date and time: Thursday, November 13 | 4:25 PM - 4:55 PM
Speakers:

• Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami
• Michael Goldberg, PhD, VP, R&D, BostonGene

“Collaborating with BostonGene allows us to apply advanced omnimodal analytics to real-world clinical challenges,” said Ola Landgren, MD, PhD, director of the Sylvester Myeloma Institute and professor of medicine with the Miller School of Medicine. “By integrating genomic, transcriptomic and immune data into a unified platform, we can identify the right patients for the right trials, uncover novel biomarkers and generate stronger evidence to guide therapy decisions-all of which demonstrates how AI-driven insights can de-risk and accelerate the clinical development of innovative treatments.”

“AMP is the ideal forum for showcasing innovations that advance molecular diagnostics and improve patient care,” said Michael Goldberg, PhD, VP of R&D at BostonGene. “Our natively omnimodal AI model brings together clinical, genomic and immune data to reveal the true biology of each tumor and its immune system. Powered by a comprehensive, continuously trained clinical database, it helps researchers prioritize indications, stratify and select patients, predict and manage safety risks and refine endpoints-reducing trial risk and accelerating development timelines.”

Visit the AMP 2025 Annual Meeting & Expo website for more information.

About BostonGene Corporation

BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.

Fonte: Business Wire